Standardised Outcomes in Nephrology - Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
09 Sep 2021
Historique:
received: 17 03 2021
accepted: 27 08 2021
entrez: 10 9 2021
pubmed: 11 9 2021
medline: 14 9 2021
Statut: epublish

Résumé

Globally, over 1.2 million people die from chronic kidney disease (CKD) every year. Patients with CKD are up to 10 times more likely to die prematurely than progress to kidney failure requiring kidney replacement therapy. The burden of symptoms and impaired quality of life in CKD may be compounded by comorbidities and treatment side effects. However, patient-important outcomes remain inconsistently and infrequently reported in trials in patients with CKD, which can limit evidence-informed decision-making. The Standardised Outcomes in Nephrology - Chronic Kidney Disease (SONG-CKD) aims to establish a consensus-based core outcome set for trials in patients with CKD not yet requiring kidney replacement therapy to ensure outcomes of relevance to patients, caregivers and health professionals are consistently reported in trials. SONG-CKD involves four phases: a systematic review to identify outcomes (domains and measures) that have been reported in randomised controlled trials involving adults with CKD who do not require kidney replacement therapy; stakeholder key informant interviews with health professionals involved in the care of adults with CKD to ascertain their views on establishing core outcomes in CKD; an international two-round online Delphi survey with patients, caregivers, clinicians, researchers, policy makers and industry representatives to obtain consensus on critically important outcome domains; and stakeholder consensus workshops to review and finalise the set of core outcome domains for trials in CKD. Establishing a core outcome set to be reported in trials in patients with CKD will enhance the relevance, transparency and impact of research to improve the lives of people with CKD. Not applicable. This study is registered with the Core Outcome Measures in Effectiveness Trials (COMET) database: http://www.comet-initiative.org/Studies/Details/1653 .

Sections du résumé

BACKGROUND BACKGROUND
Globally, over 1.2 million people die from chronic kidney disease (CKD) every year. Patients with CKD are up to 10 times more likely to die prematurely than progress to kidney failure requiring kidney replacement therapy. The burden of symptoms and impaired quality of life in CKD may be compounded by comorbidities and treatment side effects. However, patient-important outcomes remain inconsistently and infrequently reported in trials in patients with CKD, which can limit evidence-informed decision-making. The Standardised Outcomes in Nephrology - Chronic Kidney Disease (SONG-CKD) aims to establish a consensus-based core outcome set for trials in patients with CKD not yet requiring kidney replacement therapy to ensure outcomes of relevance to patients, caregivers and health professionals are consistently reported in trials.
METHODS METHODS
SONG-CKD involves four phases: a systematic review to identify outcomes (domains and measures) that have been reported in randomised controlled trials involving adults with CKD who do not require kidney replacement therapy; stakeholder key informant interviews with health professionals involved in the care of adults with CKD to ascertain their views on establishing core outcomes in CKD; an international two-round online Delphi survey with patients, caregivers, clinicians, researchers, policy makers and industry representatives to obtain consensus on critically important outcome domains; and stakeholder consensus workshops to review and finalise the set of core outcome domains for trials in CKD.
DISCUSSION CONCLUSIONS
Establishing a core outcome set to be reported in trials in patients with CKD will enhance the relevance, transparency and impact of research to improve the lives of people with CKD.
TRIAL REGISTRATION BACKGROUND
Not applicable. This study is registered with the Core Outcome Measures in Effectiveness Trials (COMET) database: http://www.comet-initiative.org/Studies/Details/1653 .

Identifiants

pubmed: 34503563
doi: 10.1186/s13063-021-05574-1
pii: 10.1186/s13063-021-05574-1
pmc: PMC8427149
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

612

Subventions

Organisme : National Health and Medical Research Council
ID : 1092597

Informations de copyright

© 2021. The Author(s).

Références

Am J Kidney Dis. 2020 Sep;76(3):361-373
pubmed: 32359822
J Pediatr. 2017 Jul;186:110-117.e11
pubmed: 28449820
J Gen Intern Med. 2011 Apr;26(4):379-85
pubmed: 20853156
Eur Spine J. 2015 Jun;24(6):1127-42
pubmed: 25841358
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
Kidney Int. 2018 Dec;94(6):1053-1068
pubmed: 30360959
Am J Kidney Dis. 2020 Mar;75(3):404-412
pubmed: 31955922
Lancet. 2017 Oct 21;390(10105):1888-1917
pubmed: 28434650
Transplantation. 2018 Dec;102(12):2065-2071
pubmed: 29781954
Am J Kidney Dis. 2017 Oct;70(4):464-475
pubmed: 28238554
PLoS Med. 2011 Jan 25;8(1):e1000393
pubmed: 21283604
Pharmacoeconomics. 2016 Dec;34(12):1195-1209
pubmed: 27402349
Am J Kidney Dis. 2017 Jan;69(1):97-107
pubmed: 27497527
Am J Kidney Dis. 2016 Jun;67(6):851-60
pubmed: 26706255
Kidney Int. 2017 Aug;92(2):297-305
pubmed: 28709600
J Clin Epidemiol. 2014 Jul;67(7):745-53
pubmed: 24582946
Perit Dial Int. 2020 Mar;40(2):132-140
pubmed: 32063197
Obstet Gynecol. 2016 Jan;127(1):49-58
pubmed: 26646133
Am J Kidney Dis. 2018 Jul;72(1):62-74
pubmed: 29475768
Trials. 2015 Mar 04;16:76
pubmed: 25887437
Am J Kidney Dis. 2014 Sep;64(3):338-46
pubmed: 24768353
Transplantation. 2017 Aug;101(8):1887-1896
pubmed: 28737661
Kidney Int. 2019 Sep;96(3):699-710
pubmed: 31200941
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Lancet. 2017 Mar 25;389(10075):1238-1252
pubmed: 27887750
Trials. 2015 Aug 20;16:368
pubmed: 26289560
Nephrol Dial Transplant. 2021 May 27;36(6):1048-1056
pubmed: 32170940
BMJ. 1995 Aug 5;311(7001):376-80
pubmed: 7640549
Clin Kidney J. 2016 Jun;9(3):494-502
pubmed: 27274839
Am J Kidney Dis. 2020 Oct;76(4):533-545
pubmed: 32654889
Am J Kidney Dis. 2020 Nov;76(5):679-689
pubmed: 32492463
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Am J Kidney Dis. 2020 Aug;76(2):213-223
pubmed: 32171640
Transplantation. 2017 Nov;101(11):2765-2773
pubmed: 29064956
Transplantation. 2017 Aug;101(8):1875-1886
pubmed: 28738403
N Engl J Med. 2020 Jun 25;382(26):2504-2513
pubmed: 32579811
Lancet. 2019 May 11;393(10184):1937-1947
pubmed: 30995972

Auteurs

Nicole Evangelidis (N)

Sydney School of Public Health, The University of Sydney, Sydney, Australia. nicole.evangelidis@sydney.edu.au.
Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia. nicole.evangelidis@sydney.edu.au.

Benedicte Sautenet (B)

Department of Nephrology, CHU Tours, INSERM SPHERE U1246, University of Tours, University of Nantes, Tours, France.

Magdalena Madero (M)

Division of Nephrology, Department of Medicine, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.

Allison Tong (A)

Sydney School of Public Health, The University of Sydney, Sydney, Australia.
Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.

Gloria Ashuntantang (G)

Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon.

Laura Cortes Sanabria (LC)

Unidad de Investigación Médica en Enfermedades Renales, Hospital de Especialidades, CMNO, IMSS, Guadalajara, Mexico.

Ian H de Boer (IH)

Department of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA.

Samuel Fung (S)

Division of Nephrology, Department of Medicine & Geriatrics, Princess Margaret Hospital, Hong Kong, Hong Kong.

Daniel Gallego (D)

Federacion Nacional ALCER (Spanish Kidney Patient's Federation), Madrid, Spain.

Andrew S Levey (AS)

Division of Nephrology, Tufts Medical Center, Boston, MA, USA.

Adeera Levin (A)

Division of Nephrology, University of British Columbia, Vancouver, Canada.

Eduardo Lorca (E)

Department of Nephrology, Hospital Salvador, Santiago, Chile.

Ikechi G Okpechi (IG)

Division of Nephrology and Hypertension, University of Cape Town, Cape Town, South Africa.
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Patrick Rossignol (P)

Université de Lorraine, Inserm, Centre d'Investigations Clinique 1433 and Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT, Nancy, France.

Laura Sola (L)

Dialysis Unit, CASMU-IAMPP, Montevideo, Uruguay.

Tim Usherwood (T)

The University of Sydney, Westmead Clinical School, Westmead, NSW, Australia.
The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.

David C Wheeler (DC)

Centre for Nephrology, UCL Medical School, London, UK.

Yeoungjee Cho (Y)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Australasian Kidney Trials Network, Centre for Health Services Research, University of Queensland, Brisbane, QLD, Australia.
Translational Research Institute, Brisbane, QLD, Australia.

Martin Howell (M)

Sydney School of Public Health, The University of Sydney, Sydney, Australia.
Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.

Chandana Guha (C)

Sydney School of Public Health, The University of Sydney, Sydney, Australia.
Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.

Nicole Scholes-Robertson (N)

Sydney School of Public Health, The University of Sydney, Sydney, Australia.
Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.

Katherine Widders (K)

Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.

Andrea Matus Gonzalez (AM)

Sydney School of Public Health, The University of Sydney, Sydney, Australia.
Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.

Armando Teixeira-Pinto (A)

Sydney School of Public Health, The University of Sydney, Sydney, Australia.
Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.

Andrea K Viecelli (AK)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Australasian Kidney Trials Network, Centre for Health Services Research, University of Queensland, Brisbane, QLD, Australia.

Amelie Bernier-Jean (A)

Sydney School of Public Health, The University of Sydney, Sydney, Australia.
Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.

Samaya Anumudu (S)

Selzman Institute for Kidney Health, Section of Nephrology, Baylor College of Medicine, Houston, TX, USA.

Louese Dunn (L)

Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Martin Wilkie (M)

Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Jonathan C Craig (JC)

College of Medicine and Public Health, Flinders University, Adelaide, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH